CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 120 enrolled
Drug / intervention
Vorapaxar +3 moredrug
Likely dose
Aspirin 325 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00684203
NCT00684203Phase 2Completed
CompareCT.gov

Phase II Study of SCH 530348 in Subjects With Acute Coronary Syndrome

Merck Sharp & Dohme LLC·interventional·Posted May 26, 2008·Updated May 5, 2017

In Brief

A Phase 2 clinical trial evaluating Vorapaxar, Placebo, and 2 other interventions for Atherosclerosis and 2 related conditions. Completed, enrolled 120 participants.

Detailed Summary

The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome. The study may also provide information about the effect of vorapaxar on preventing heart attack and stroke in this subject population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis, Myocardial Ischemia, Myocardial Infarction
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 26, 2008
Enrollment StartDec 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.1 years ago

Interventions

Vorapaxardrug

Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days

Placebodrug

Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days

Aspirindrug

Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.

Clopidogreldrug

100 mg two or three times daily for 60 days.